Loading
Heart Failure Treatment and Management / Diabetes Treatment and Management / Chronic Kidney Disease and Diabetes · Journal article
Cardiology in Review · August 3, 2026
A consensus or society position rather than new primary data.
This is a clinical narrative review of SGLT2 inhibitors in cardiology, documenting their evolution from antihyperglycemic agents to foundational therapies for heart failure and chronic kidney disease. The source confirms consistent benefit for reducing heart failure hospitalization and slowing CKD progression across multiple phenotypes, but acknowledges that effects on major adverse cardiovascular events, myocardial infarction, stroke, and arrhythmias remain incompletely defined and variable.
Narrative review. Patients with type 2 diabetes mellitus, heart failure (across ejection fraction phenotypes), and chronic kidney disease, including those without diabetes. Intervention: SGLT2 inhibitors (pharmacology, mechanisms, and clinical outcomes).
Most consistent benefits are reducing heart failure hospitalization and slowing chronic kidney disease progression, including in patients without diabetes Effects on major adverse cardiovascular events, myocardial infarction, stroke, arrhythmias, and postmyocardial infarction outcomes remain more variable and incompletely defined SGLT2 inhibitors are now central to guideline-directed medical therapy in heart failure across reduced, mildly reduced, and preserved ejection fraction phenotypes
Safety profile mentioned but not detailed in this abstract Effects on major adverse cardiovascular events, myocardial infarction, stroke, arrhythmias, and postmyocardial infarction outcomes remain more variable and incompletely defined
Clinicians should recognize SGLT2 inhibitors as established first-line therapy for heart failure and CKD with renal protection benefits. However, heterogeneity in effects on MACE, MI, stroke, and arrhythmias requires individualized assessment and caution against overgeneralization of benefits beyond heart failure hospitalization and CKD slowing.
A narrative review synthesizing mechanisms and trial evidence for SGLT2 inhibitors across heart failure and CKD, positioning them as foundational therapies; evidence quality varies by outcome and lacks quantified effect sizes.
As stated by the source record.
Clinicians should recognize SGLT2 inhibitors as established first-line therapy for heart failure and CKD with renal protection benefits. However, heterogeneity in effects on MACE, MI, stroke, and arrhythmias requires individualized assessment and caution against overgeneralization of benefits beyond heart failure hospitalization and CKD slowing.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors were initially developed as antihyperglycemic agents for type 2 diabetes mellitus but have become foundational therapies in cardiovascular and cardiorenal medicine. Randomized trials and meta-analyses show their most consistent benefits are reducing heart failure hospitalization and slowing chronic kidney disease progression, including in patients without diabetes. In contrast, their effects on major adverse cardiovascular events, myocardial infarction, stroke, arrhythmias, and postmyocardial infarction outcomes remain more variable and incompletely defined. Mechanistically, SGLT2 inhibitors act through natriuresis, osmotic diuresis, plasma-volume redistribution, improved renal hemodynamics, reduced ventricular loading, attenuation of inflammation and fibrosis, and possible improvements in myocardial energetics and vascular biology. In heart failure, they are now central to guideline-directed medical therapy across reduced, mildly reduced, and preserved ejection fraction phenotypes, with increasing support for early in-hospital initiation in selected patients. In chronic kidney disease, they link renal protection with meaningful cardiovascular benefit, particularly for heart failure outcomes. This review summarizes their pharmacology, mechanisms, cardiovascular evidence, safety, implementation challenges, and future directions in precision cardiorenal therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.